Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-10-16
2011-10-11
Shiao, Rei-tsang (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S315000, C514S357000, C514S381000, C514S383000, C548S262200, C548S250000, C548S255000, C546S329000, C546S184000
Reexamination Certificate
active
08034810
ABSTRACT:
α-Amino hydroxamic acid derivative of the formula I,in which R is C2-C7-alkyl, which is mono-, di- or trisubstituted by halogen, nitro, lower acyloxy, trifluoromethoxy, cyano, C3-C5-cycloalkyl or unsubstituted or substituted C3-C6-heteroaryl comprising one or two heteroatoms selected from the group consisting of O, S and N; or C3-C7-alkenyl or C3-C7-alkynyl, which in each case is unsubstituted or mono-, di- or trisubstituted by halogen, nitro, lower acyloxy, trifluoromethoxy, cyano, C3-C5-cycloalkyl or unsubstituted or substituted C3-C6-heteroaryl comprising one or two heteroatoms selected from the group consisting of O, S and N;and the other symbols are as defined in claim1,are described.These compounds are MMP and in particular MMP2 inhibitors and can be used for treatment of MMP dependent diseases, in particular inflammation conditions, rheumatoid arthritis, osteoarthritis, tumors (tumor growth, metastasis, progression or invasion) and pulmonary disorders (e.g. emphysema, COPD).
REFERENCES:
patent: 2513826 (1950-07-01), Sprung et al.
patent: 5455258 (1995-10-01), MacPherson et al.
patent: 5500337 (1996-03-01), Benard et al.
patent: 5646167 (1997-07-01), MacPherson et al.
patent: 5770624 (1998-06-01), Parker
patent: 5932695 (1999-08-01), Floyd et al.
patent: 5985900 (1999-11-01), Bender et al.
patent: 6150394 (2000-11-01), Watanabe et al.
patent: 6159995 (2000-12-01), Thorwart et al.
patent: 6451824 (2002-09-01), Thorwart et al.
patent: 7138432 (2006-11-01), Breitenstein et al.
patent: 306453 (1989-03-01), None
patent: 308860 (1989-03-01), None
patent: 469984 (1992-02-01), None
patent: 0877018 (1998-11-01), None
patent: 0877019 (1998-11-01), None
patent: 915086 (1999-05-01), None
patent: 0930067 (1999-07-01), None
patent: 0949244 (1999-10-01), None
patent: 2686878 (1993-08-01), None
patent: WO 96/00214 (1996-01-01), None
patent: WO 97/44315 (1997-11-01), None
patent: WO 98/18754 (1998-05-01), None
patent: WO 98/25597 (1998-06-01), None
patent: WO 98/33768 (1998-08-01), None
patent: WO 98/47494 (1998-10-01), None
patent: WO 99/06340 (1999-02-01), None
patent: WO 99/42443 (1999-08-01), None
patent: WO 00/44709 (2000-08-01), None
patent: WO 00/44713 (2000-08-01), None
Parker's, 1998, CAS: 129:81961.
MacPherson et al., 1997, CAS: 127:117057.
MacPherson et al., 1997, CAS: 127: 162116.
Y. Tamura et al., J. Med. Chem, vol. 41, No. 4, pp. 640-649, XP002151755 (1998).
J. H. Uhlenbroek et al., RECL. TRAV. CHIM.PAYS-BAS, vol. 75, pp. 129-146, XP000953403 (1956).
Scozzafava et al., “Protease Inhibitors: Synthesis of Potent Bacterial Collagenase and Matrix Metalloproteinase Inhibitors Incorporating N-4-nitrobenzylsulphonylglycine Hydroxamate Moieties,” J. Med. Chem., vol. 43, No. 9, pp. 1858-1865 (2000).
MacPherson et al., “Discovery of CGS 27023A, Non-Peptidic Potent and Orally Active Stromelysin Inhibitor That Blocks Cartilage Degradation in Rabbits,” J. Med. Chem., vol. 40, pp. 2525-2532 (1997).
Casini et al., “Sulfonamides and sulfonylated derivatives as anticancer agents,” Current Cancer Drug Targets, vol. 2, pp. 55-75, especially p. 58 (2002).
Tamura et al., “Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-Sulfonylamino acid derivatives,” vol. 41, pp. 640-649, especially p. 640. (1998).
Connell et al., “Patent focus on cancer chemotherapeutics. II Angiogenesis agents: Apr. 2000-Sep. 2000,” vol. 11(1), pp. 77-114, especially p. 84 (2001).
Breitenstein Werner
Hayakawa Kenji
Iwasaki Genji
Kanazawa Takanori
Kasaoka Tatsuhiko
Alexander John B.
Novartis AG
Shiao Rei-tsang
LandOfFree
Arylsulfonamido-substituted hydroxamic acid derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Arylsulfonamido-substituted hydroxamic acid derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arylsulfonamido-substituted hydroxamic acid derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4288553